A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery

Vergote, Ignace; Oaknin, A; Baurain, J-F; Ananda, S; Wong, Shing Yee; Su, X; Wu, Bin; Zhong, Z; Warner, D; Casado, A

doi:10.1016/j.ejca.2014.06.010

A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery

Author:

Vergote, Ignace

Oaknin, A ; Baurain, J-F ; Ananda, S ; Wong, Shing Yee ; Su, X ; Wu, Bin ; Zhong, Z ; Warner, D ; Casado, A

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Angiogenesis inhibitors, Angiopoietin-1, Angiopoietin-2, Tie2 receptor, Combination drug therapy, ADVANCED SOLID TUMORS, ENDOTHELIAL GROWTH-FACTOR, AMG 386, NEOADJUVANT CHEMOTHERAPY, DOUBLE-BLIND, ANGIOGENESIS, ANGIOPOIETIN-1, BEVACIZUMAB, INHIBITION, CARCINOMA, Adult, Aged, Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Cohort Studies, Combined Modality Therapy, Female, Humans, Middle Aged, Ovarian Neoplasms, Paclitaxel, Recombinant Fusion Proteins, Treatment Outcome, 1112 Oncology and Carcinogenesis, 1117 Public Health and Health Services, Oncology & Carcinogenesis, 3211 Oncology and carcinogenesis

Abstract:

To evaluate the tolerability, pharmacokinetics and tumour response of first-line trebananib plus paclitaxel and carboplatin followed by trebananib maintenance in high-risk or advanced ovarian cancer.